About us

We are a clinical-stage Biotech with a Focus on COVID-19 Vaccine Development

Located at the heart of Frankfurt am Main, Speransa Therapeutics is led by a dedicated and highly-specialized team, with a strong background in biopharmaceutical research, development and manufacturing.

The Company is backed by the Boehringer Ingelheim Venture Fund and partners with leading academic institutions such as the University Hospital Tübingen.

Prime-2-CoV_Beta, our lead COVID-19 vaccine candidate, was originally developed at the University of Tübingen, Germany. It is based on a highly attenuated and non-pathogenic live viral vector D1701-VrV derived from an ORF virus isolate. Used for 20 years in biomedical research and veterinary medicine, this vector has highly beneficial characteristics for the development of a COVID-19 vaccine.


The research and development of an innovative, potent and polyvalent COVID-19 vaccine based on the ORF virus as a platform technology for COVID-19 vaccines is a project funded by the EXIST program.

EXIST is a support program of the German Federal Ministry for Economic Affairs and Climate Action (BMWK). It aims at improving the entrepreneurial environment at universities and research institutes as well as increasing the number and success of technology- and knowledge-based business start-ups.

For the last 20 years, the Federal Ministry for Economic Affairs and Energy has been successfully using the “EXIST –Business start-ups in science” program to fund start-up spin-offs from German universities and science.

For further Information on the EXIST program click here

Our Partners

Through research and development collaborations, partnerships with pharmaceutical and biotech companies, as well as academia and clinics, we aim to fully leverage our technology with cutting edge science and advance vaccine research and development.
Click here to contact us about partnering with Speransa Therapeutics.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation. Since 2010, the Boehringer Ingelheim Venture Fund invests in pioneering science that offers the potential to provide a significant benefit for patients.
Founded in 1805, the University Hospital Tuebingen is one of the leading centres of German university medicine. As one of 35 University Hospitals in Germany, it contributes to a successful combination of top-level medicine, research, and teaching. Its experts collaborate across disciplines and offer state-of-the-art treatment to more than 400,000 in- and outpatients from around the world each year. Neurosciences, Oncology and Immunology, Infection Biology, Vascular Medicine and Diabetes are focus areas of research at the University Hospital Tuebingen. It is a reliable partner in four of the six German Centres for Health Research (DZG) created by the Federal Government.
Prime Vector Technologies GmbH was founded in 2019 as a Spin-Off from the Department of Immunology at the University of Tübingen. Prime Vector Technologies is a research and development company that develops a viral platform technology for the production of human and veterinary vaccines against infectious diseases and cancer.